Figure 1



PR
SD
PD
(RECIST 1.1)
On treatment
Response first achieved
Unconfirmed iPR*
*Based on irRECIST
Weeks
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
+ cAXL positive
- cAXL negative
NE: Non-evaluable
Previous immunotherapy (1 or 2L)
P: pembrolizumab; A: atezolizumab; N: nivolumab; C: cetrelimab; I: ipilumimab; O: other
Data cut-off: 17-April-2020

Figure 2



cAXL+ve
cAXL−ve
Median: 4.73 mo
Median: 1.87mo
p = 0.066
Log-rank test
Fraction at risk
1.00
0.75
0.50
0.25
0
Time (months)
0
1
2
3
4
5
6
7
8
9
10

Figure 3





Figure 4




Figure 5





Figure 6




Figure 7a





Figure 7b




Figure 7c





Figure 7d




Figure 8a





Figure 8b




Figure 8c





Figure 8d

| | Stem | Clonal Expanded | Exhaustive Effector |
|---|---|---|---|
| Ctrl | + | - | + |
| BGB324 | ++ | +++ | ++ |
| PD-1 | ++ | - | - |
| Combined | - | + | + |

Figure 8e



3.1
15.5
3.1
5.8
15.5
5.8
2-Ex. activated
5-Stem
7-Clonal Expanded
2
5
7
Clonal expanded
Stem
Ex. Activated

Figure 9a





Figure 9b




Figure 9c





Figure 9d




Figure 9e





Figure 9f




Figure 9g





Figure 9h

